Ridgeway Acquisition Corporation agreed to acquire Verve Therapeutics, Inc. from Sekar Kathiresan, Andrew Ashe, and entities affiliated with GV for $10.50 per share in cash, totaling approximately $1 billion, plus a contingent value right (CVR) for up to an additional $3.00 per share. The total potential consideration is up to $1.3 billion. The transaction, approved by both companies' boards, is expected to close in Q3 2025, subject to customary conditions. Verve faces a termination fee of $39.7 million.

Eli Lilly is considering acquiring Verve Therapeutics for $1.3 billion, potentially doubling Verve's market value. The deal includes an upfront payment of nearly $1 billion and $300 million tied to clinical milestones. Verve's shares surged over 82% in premarket trading. This move signals Eli Lilly's entry into the gene-editing market, reflecting broader trends in healthcare innovation and potentially encouraging other major players to explore similar strategies.

The CRISPR RevolutionCRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a recently discovered tool for genetic editing. It allows for very precise and directed gene editing, and its discoverers have won the 2020 Nobel Prize.The initial CRISPR system discovered was CRISPR-Cas9, and many modified CRISPR systems have been discovered or created since. You can read more about the technical details of CRISPR in our article “What Is CRISPR-Cas12a2? Why Does It Matter?”CRISPR is at the forefront of the genomic revolution, with the first gene therapies using it now getting approved for blood diseases, something we explored in depth in “How CRISPR Companies Target Sickle Cell Anemia”.Almost every month that passes seems to bring a brand new revolutionary CRISPR therapy or application. The latest in date is curing a rare form of blindness.Curing Blindness With CRISPR?In a scientific paper titled “Gene Editing for CEP290-Associated Retinal Degeneration”, researchers and doctors at the Universities of Harvard Medical School, Pennsylvania, Michigan, Miami, Oregon Health and Science, as well as Perelman School of Medicine and Editas Medicine have seen remarkable results in treating a disease called Leber Congenital Amaurosis (LCA)LCA causes the degradation of the vision in the first early months of life. There is currently no treatment for LCA, and affects an estimated 50,000 people in the USA and 180,000 people worldwide.After a break in 2022,  Editas Medicine announced in May 2024 that the clinical trial for EDIT-101 has seen 79% of the 14 clinical trial participants experience measurable improvement after receiving the experimental gene therapy.“One of our trial participants has shared several examples, including being able to find their phone after misplacing it and knowing that their coffee machine is working by seeing its small lights.While these types of tasks might seem trivial to those who are normally sighted, such improvements can have a huge impact on quality of life for those with low vision.” – Mark Pennesi, M.D., Ph.D. – Oregon Health Science University’s lead scientistNext Steps For EDIT-101Now that the efficiency of the treatment is proven, and there were no serious side effects, the next step is determining the “ ideal dosing, whether a treatment effect is more pronounced in certain age groups such as younger patients, and include refined endpoints to measure impacts on activities of daily living.”“Our hope is that the study will pave the road for treatments of younger children with similar conditions and further improvements in vision.This trial represents a landmark in the treatment of genetic disease, in specific genetic blindness, by offering important alternative treatment when traditional forms of therapy, such as gene augmentation, are not an option.” – Tomas S. Aleman, M.D